Actively Recruiting
Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization
Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2026-04-02
188
Participants Needed
1
Research Sites
309 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine the effectiveness of therapeutic dose intravenous heparin at improving replantation/revascularization success and its indications (if any) in participants who have suffered traumatic digital amputation. Digital replantation/revascularization success will be assessed in participants who receive continuous intravenous drip of thromboprophylactic heparin at a therapeutic dose (i.e. modifies INR to the desired range) contrasted to those who do not receive therapeutic dose heparin (i.e. does not modify INR to the desired range). In the study, replantation/revascularization success is defined as a clearly viable digit at the time of discharge. Secondary objectives include assessing postoperative complications associated with heparin use, such as bleeding, hematoma or heparin induced thrombocytopenia. The investigators would also assess the impact of categorical variables such as smoking status, mechanism of injury and comorbidities, on digital survival.
CONDITIONS
Official Title
Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All replantation and revascularization patients accepted into the CEVARMU program at the Centre hospitalier de l'Université de Montréal
You will not qualify if you...
- Patients on anticoagulants other than aspirin prior to admission (e.g., Coumadin, Eliquis, Pradaxa, Plavix)
- Patients with contraindications to heparin, including coagulopathy, acute ulcers, thrombocytopenia, severe liver damage, or shock
- Patients with amputations at or above the carpal tunnel level
- Patients who suffered degloving injuries
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHUM
Montreal, Quebec, Canada, H2X 3E4
Actively Recruiting
Research Team
L
Linda M Zhu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here